Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.30
+0.09007.44%
Post-market: 1.28-0.0200-1.54%19:59 EDT
Volume:2.81M
Turnover:3.61M
Market Cap:17.17M
PE:-1.16
High:1.36
Open:1.20
Low:1.16
Close:1.21
Loading ...

Hoth Therapeutics Secures New Patent Filing for Innovative HT-001 Formulation, Strengthening IP Portfolio in Cancer Care

Reuters
·
05 Jun

Hoth Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Christopher Michael Camarra

Reuters
·
22 May

Hoth Therapeutics Faces Nasdaq Compliance Challenge

TIPRANKS
·
17 May

Hoth Therapeutics Inc. Faces Nasdaq Non-Compliance for Minimum Bid Price Requirement

Reuters
·
17 May

Hoth Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Hoth Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
10 May

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

PR Newswire
·
17 Apr

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
15 Apr

BRIEF-Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial

Reuters
·
15 Apr

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

THOMSON REUTERS
·
15 Apr

Hoth Therapeutics Inc - Patients Experienced a 50% Reduction in Pruritus Severity, With Mean Scores Dropping From 1.6 on Day 1 to 0.8 by Day 21

THOMSON REUTERS
·
15 Apr

Hoth Therapeutics Inc - Ht-001 Was Well Tolerated, With No Treatment-Related Serious Adverse Events Reported

THOMSON REUTERS
·
15 Apr

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

PR Newswire
·
15 Apr

Hoth Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
03 Apr

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

PR Newswire
·
02 Apr

Hoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZ

TIPRANKS
·
02 Apr

BRIEF-Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development

Reuters
·
02 Apr

Hoth Therapeutics Announces Positive Pre Clinical Data Ht-Alz Shows Promising Breakthrough in Alzheimer's Disease Research Acute Treatment With Ht-Alz Led to a Rapid (~15%) Reduction in Brain Interstitial Fluid aΒ Levels, Within 20 Hours

THOMSON REUTERS
·
02 Apr

Hoth Therapeutics - Plans to Advance Ht-Alz Into Clinical Development

THOMSON REUTERS
·
02 Apr

BRIEF-Hoth Therapeutics Receives Uspto Filing Receipt For Ht-001 Formulation Patent Application, Expanding Existing Patent Coverage

Reuters
·
01 Apr